R&D Life Sciences Industry Report 2025 - GLP-1S: Applicability i... The pharmaceutical landscape in 2024 was undeniably shaped by the remarkable rise of GLP-1 receptor agonists.
News Nine-month-old obesity player Metsera files an IPO Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs.
News Verdiva Bio raises $411m for obesity pipeline A new obesity startup – Verdiva Bio – has just decloaked with a whopping $411m to advance a once-weekly oral GLP-1 agonist.
News Novo Nordisk swells alliance with AI firm Valo Health Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn.
News Novo Nordisk asks FDA not to allow GLP-1 compounding Novo Nordisk has asked the FDA to block compounders from making versions of its older, once-daily GLP-1 agonist liraglutide.
News Lilly grabs first-ever FDA nod for a sleep apnoea drug Lilly's Zepbound has become the first drug approved by the FDA for obese patients with obstructive sleep apnoea, which affects millions in the US.
News Threat of Trump's pharma tariffs looms again The Trump administration is said to be preparing to announce tariffs of up to 100% on some pharmaceutical imports.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
